Clinical Trial Update: Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose metronomic cyclophosphamide in combination with capecitabine for pretreatment HER2-negative metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Capecitabine (capecitabine)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN